CMS: announces drugs selected for third cycle of Medicare price negotiations — Rexulti, Trulicity, Verzenio, Xeljanz, Xeljanz XR, Xolair; Tradjenta chosen for renegotiation

martes, 27 de enero de 2026, 4:40 pm ET1 min de lectura

CMS: announces drugs selected for third cycle of Medicare price negotiations — Rexulti, Trulicity, Verzenio, Xeljanz, Xeljanz XR, Xolair; Tradjenta chosen for renegotiation

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios